TZAR
LABS
UK

Tzar Labs UK
has opened in London

Tzar Labs have opened their laboratory in London, joining the Singapore and Indian facilities. The HrC Genomics cancer screening test and the BCube Tests for cancer, diabetes, cardiovascular disease, and neurodegenerative disease are now available.

Please contact Steve Smith with any inquiries on 020 8050 2578 or contact.uk@tzarlabs.com
The HrC Genomics Test

The HrC Genomics test is a breakthrough blood test which evaluates the expression levels of rare stem cell markers which may be indicative of cancer. Capable of detecting all cancer types in a single blood test, it has a sensitivity/accuracy of 90% plus, including at Stage One. The HrC Genomics test provides an indication of the likelihood of the presence or absence of cancer. It has won the 2025 Edison Gold Award for Innovation.

The BCube Tests

The B-Cube Tests are geno-molecular analyses that use transcriptome based NGS data focused on disease-linked markers and genetic pathways. A comprehensive report (approximately 20-30 pages) is provided, with an optional Orthomolecular and Pharmacotranscriptomic Report available for clinicians, detailing possible intervention options. A clinician may use this report in conjunction with other “standard of care” tests.

The BCube Tests currently available are:
• BCube Onco

BCube Onco is a BCube test focusing on cancer, providing more detailed information than the HrC screening test. This test can be used by cancer survivors to monitor recurrence and/or remission, and also by active cancer patients to monitor treatment efficacy.

• BCube Diabetes

For diabetic and pre-diabetic patients, for assistance in the management of their condition.

• BCube Cardiac

This test evaluates the risk of and/or current status of a variety of neurodegenerative diseases, including Alzheimers, Parkinsons and Huntingtons Disease.

• BCube Neuro

This test evaluates the risk/status of neurodegenerative diseases, including Alzheimer's, Parkinson's, and Huntington's Disease.

Edison Gold Award 2025